Table 3.
Estimated monoclonal antibody use according to total global sales and average global cost
| mAb | Total global sales in 2018 (US$, $m)a | Mean global mAb cost [US$ (min–max)]b | Average estimated mAb yearly users across the years 2013–2018 [in thousands (min–max)] |
|---|---|---|---|
| Adalimumab | 19,952 | 34,870 (14,141–55,614) | 615 (331–1524) |
| Etanercept | 7611 | 30,105 (11,085–49,142) | 276 (149–713) |
| Pembrolizumab | 7171 | 107,625 (80,214–135,072) | 68 (40–109) |
| Trastuzumab | 7053 | 47,119 (19,869–74,389) | 160 (90–367) |
| Bevacizumab | 6919 | 86,810 (36,383–137,278) | 84 (49–193) |
| Rituximab | 6821 | 23,559 (6323–38,153) | 305 (172–1102) |
| Aflibercept | 6746 | 38,425 (9378–67,491) | 187 (77–818) |
| Nivolumab | 6735 | 102,425 (40,614–164,291) | 70 (37–179) |
| Infliximab | 6593 | 22,790 (15,730–29,854) | 297 (209–440) |
| Ustekinumab | 5156 | 28,586 (15,280–42,415) | 190 (86–435) |
| Denosumab | 4077 | 13,069 (3804–22,341) | 325 (131–1286) |
| Ranibizumab | 3722 | 32,341 (10,187–54,514) | 125 (63–396) |
| Eculizumab | 3563 | 547,771 (509,185–586,412) | 7 (3–10) |
| Golimumab | 2977 | 33,712 (15,244–52,192) | 94 (51–216) |
| Omalizumab | 2970 | 26,148 (12,696–39,619) | 121 (61–277) |
| Abatacept | 2710 | 28,158 (18,677–37,653) | 99 (63–162) |
| Tocilizumab | 2182 | 28,920 (15,782–42,081) | 79 (34–187) |
| Natalizumab | 1864 | 47,775 (22,463–73,110) | 41 (23–89) |
| Cetuximab | 1451 | 80,792 (15,351–146,256) | 19 (9–103) |
| Certolizumab pegol | 1446 | 34,460 (11,632–50,322) | 45 (17–163) |
| Palivizumab | 1381 | 22,914 (9139–36,697) | 63 (34–167) |
| Iplimumab | 1330 | 123,321 (114,373–132,282) | 11 (8–14) |
mAb monoclonal antibody, US$ United States dollars, GBP Great British pound, max maximum, min minimum
a2013–2018 global sales were used to calculate the estimated monoclonal antibody yearly users. 2018 data are shown here
bMaximum value is based on electronic supplementary Table S2, while minimum value is based on electronic supplementary Table S3, with 1 GBP converted to 1.524 US$